Difference between revisions of "Team:BGU Israel/Safety"

 
(14 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
{{BGU_Israel}}
 
{{BGU_Israel}}
  
 
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
 
 
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
 
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  
 +
  <head>
  
<body  class="mediawiki  ltr ns-0 ns-subject page-Team_BGU_Israel_Team">
+
    <!-- Scripts -->
  <div id="globalWrapper">
+
    <script type="text/javascript"
  <div id='top_menu_under' class='noprint'></div>
+
            src="https://2015.igem.org/Template:BGU_Israel/js/TUM13_jquery-1.10.2?action=raw&ctype=text/javascript">
 +
    </script>
 +
    <script type="text/javascript"
 +
            src="https://2015.igem.org/Template:BGU_Israel/js/TUM13_slimbox2?action=raw&ctype=text/javascript">
 +
    </script>
 +
    <script type="text/javascript"
 +
            src="https://2015.igem.org/Template:BGU_Israel/js/TUM13_bxslider?action=raw&ctype=text/javascript">
 +
    </script>
 +
    <script type="text/javascript"
 +
            src="https://2015.igem.org/Template:BGU_Israel/js/TUM13_Script?action=raw&ctype=text/javascript">
 +
    </script>
 +
    <script type="text/javascript"
 +
            src="https://2015.igem.org/Template:BGU_Israel/js/TUM13_history?action=raw&ctype=text/javascript">
 +
    </script>
  
     <div id="content">
+
     <!-- Stylesheets -->
<a name="top" id="top"></a>
+
    <link rel="stylesheet" type="text/css"
<h1 class="firstHeading">Team:BGU Israel/Team</h1>
+
          href="https://2015.igem.org/Template:BGU_Israel/css/TUM13_normalize?action=raw&ctype=text/css" />
<div id="bodyContent">
+
    <link rel="stylesheet" type="text/css"
<p>
+
          href="https://2015.igem.org/Template:BGU_Israel/css/UM13_reset?action=raw&ctype=text/css" />
 
+
    <link rel="stylesheet" type="text/css"
<!-- Start of CSS-->
+
          href="https://2015.igem.org/Template:BGU_Israel/css/TUM13_slimbox2?action=raw&ctype=text/css" />
<style type="text/css">
+
    <link rel="stylesheet" type="text/css"
 
+
          href="https://2015.igem.org/Template:BGU_Israel/css/TUM13_normalize?action=raw&ctype=text/css" />
/* WIKI SETTINGS*/
+
    <link rel="stylesheet" type="text/css"
+
          href="https://2015.igem.org/Template:BGU_Israel/css/TUM13_bxslider?action=raw&ctype=text/css" />
/* Hide first heading */
+
    <link rel="stylesheet" type="text/css"
.firstHeading {
+
          href="https://2015.igem.org/Template:BGU_Israel/css/TUM13_wiki?action=raw&ctype=text/css" />
display: none;
+
    <link rel="stylesheet" type="text/css"
}
+
          href="https://2015.igem.org/Template:BGU_Israel/css/BGU15_addition?action=raw&ctype=text/css" />
+
/*-- Remove borders, float content left and remove padding/margin */
+
#globalWrapper, #content{
+
background-color: transparent;
+
border: 0px;
+
float: left;
+
margin:0px;
+
padding: 0px;
+
}
+
 
+
/*left align Black Menu Bar */
+
#top_menu_inside {
+
margin-left: 20px;
+
}
+
</style>
+
 
+
 
+
<!-- Start of CSS-->
+
<style type="text/css">
+
 
+
/* WIKI SETTINGS*/
+
+
/* Hide first heading */
+
.firstHeading {
+
display: none;
+
}
+
+
/*-- Remove borders, float content left and remove padding/margin */
+
#globalWrapper, #content{
+
background-color: transparent;
+
border: 0px;
+
float: left;
+
margin:0px;
+
padding: 0px;
+
}
+
 
+
/*left align Black Menu Bar */
+
#top_menu_inside {
+
margin-left: 20px;
+
}
+
</style>
+
</p><p><br />
+
 
+
+
    <head>
+
 
+
<!-- Scripts -->
+
<script src="http://igembgu.com/wiki/JS/TUM13_jquery-1.10.2.js?action=raw&amp;ctype=text/javascript" type="text/javascript"></script>
+
<script src="http://igembgu.com/wiki/JS/TUM13_slimbox2.js?action=raw&amp;ctype=text/javascript" type="text/javascript"></script>
+
<script src="http://igembgu.com/wiki/JS/TUM13_bxslider.js?action=raw&amp;ctype=text/javascript" type="text/javascript"></script>
+
<script src="http://igembgu.com/wiki/JS/TUM13_Script?action=raw&amp;ctype=text/javascript" type="text/javascript"></script>
+
<script src="http://igembgu.com/wiki/JS/TUM13_history.js?action=raw&amp;ctype=text/javascript" type="text/javascript"></script>
+
 
+
 
+
<!-- Stylesheets -->
+
<link href="http://igembgu.com/wiki/css/TUM13_normalize.css" type="text/css" rel="stylesheet">
+
<link href="http://igembgu.com/wiki/css/UM13_reset.css" type="text/css" rel="stylesheet">
+
<link href="http://igembgu.com/wiki/css/TUM13_slimbox2.css" type="text/css" rel="stylesheet">
+
<link href="http://igembgu.com/wiki/css/TUM13_normalize.css" type="text/css" rel="stylesheet">
+
<link href="http://igembgu.com/wiki/css/TUM13_bxslider.css" type="text/css" rel="stylesheet">
+
<link href="http://igembgu.com/wiki/css/TUM13_wiki.css" type="text/css" rel="stylesheet">
+
  
 
</head>
 
</head>
   
+
</html>
   
+
{{BGU_Israel/menu}}
 +
<html>
  
   
 
  
    <body class="mediawiki  ltr ns-0 ns-subject page-Team_BGU_Israel">   
 
      <div id="content">
 
         
 
        <img src="https://static.igem.org/mediawiki/2015/8/8f/2015igembanner.jpg" height="150px" width="100%">
 
<a name="top" id="top"></a>
 
<h1 class="firstHeading">Team:BGU Israel</h1>
 
<div id="bodyContent">
 
 
<div id="contentSub"></div>
 
<!-- start content -->
 
<p>
 
<div id="header-container">
 
   
 
    <div id="header">
 
        <table style="background-color:transparent ">
 
            <tr>
 
                <td style="width:200px"></td>
 
                <td> <img src="https://static.igem.org/mediawiki/2015/8/83/Igem_bgu_logo.png" height="120px" width="490px"><td>
 
                                                                                                                        <td></td>
 
                                                                                                                   
 
            </tr>
 
        </table>
 
    </div>
 
    <!--
 
        <a href="https://2015.igem.org/Main_Page"><img id="igem-logo" src="https://static.igem.org/mediawiki/2013/9/9c/TUM13_igem-logo.png" /></a>
 
        <a href="http://www.tum.de/en/homepage/"><img id="tum-logo" src="https://static.igem.org/mediawiki/2013/9/9b/TUM13_tum-logo.png" /></a>
 
        <a href="https://2013.igem.org/Team:TU-Munich"><img id="physco-logo" src="https://static.igem.org/mediawiki/2013/c/c4/TUM13_physco-logo-klein.png" /></a>
 
    </div>
 
  
  <!-- Start of menu -->
+
  <body class="mediawiki  ltr ns-0 ns-subject page-Team_BGU_Israel">
     <div id="menu">
+
     <div id="Div1">
        <ul>
+
            <li><a id="home" href="https://2015.igem.org/Team:BGU_Israel">Home</a></li>
+
            <li><a id="A2" href="https://2015.igem.org/Team:BGU_Israel/Team">Team</a>
+
                <!--<ul>  optional
+
                    <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Members">Members</a></li>
+
                    <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Sponsors">Sponsors</a></li>
+
                    <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Collaborations">Collaborations</a></li>
+
                    <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Gallery">Pictures</a></li>
+
                    <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Statistics">Timeline</a></li>
+
                    <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Attributions">Attributions</a></li>
+
                    <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Judging">Judging</a></li>
+
                </ul> -->
+
            </li>
+
           
+
            <li>Project
+
                            <ul>
+
                                <li><a id="A1" href="https://2015.igem.org/Team:BGU_Israel/Description">Description</a></li>
+
                              <li> <a href="https://2015.igem.org/Team:BGU_Israel/Experiments">Experiments &amp; Protocols</a>  </li>
+
                                <li><a href="https://2015.igem.org/Team:BGU_IsraelResults">Results</></a>  </li>
+
                                <li><a href="https://2015.igem.org/Team:BGU_Israel/Design">Design</a></li>
+
                            </ul>
+
            </li>
+
  
         
+
  <div id="wikicontent-container">
            <li>Parts
+
              <div id="wikicontent" style="text-align:initial !important;">
            <ul>
+
                <br />
<li><a href="https://2015.igem.org/Team:BGU_Israel/Parts">Team Parts</a></li>
+
                <br />
<li><a href="https://2015.igem.org/Team:BGU_Israel/Basic_Part">Basic Parts</a>  </li>
+
<li><a href="https://2015.igem.org/Team:BGU_Israel/Composite_Part">Composite Parts</a></li>
+
<li><a href="https://2015.igem.org/Team:BGU_Israel/Part_Collection">Part Collection</a> </li>  
+
</ul>
+
</li>
+
  
<li><a id="A3" href="https://2015.igem.org/Team:BGU_Israel/Notebook">Notebook</a></li>
+
      <!-- start HERE ---------------------------------------------------------------------------------------------------->
     
+
<p>
            <li> MORE
+
<h2>Safety</h2>
                <ul>
+
</p>
                    <li><a href="https://2015.igem.org/Team:BGU_Israel/Attributions">Attributions</a></li>
+
<p>
                  <li> <a href="https://2015.igem.org/Team:BGU_Israel/Collaborations">Collaborations</a></li>
+
<h3>Safe Project Design</h3>
                  <li> <a href="https://2015.igem.org/Team:BGU_Israel/Practices">Human practices</a></li>
+
</p>
                  <li> <a href="https://2015.igem.org/Team:BGU_Israel/Safety">Safety</a></li>
+
<p>
                  <li> <a href="https://2015.igem.org/Team:BGU_Israel/Modeling">Modeling</a></li>
+
In Boomerang project, we used bacteria, mammalian cells and virions.
                  <!-- <li> <a href="https://2015.igem.org/Team:BGU_Israel/Measurement">MEASUREMENT</a></li>
+
</p>
<!-- <a href="https://2015.igem.org/Team:BGU_Israel/Software"><li>SOFTWARE</li></a> -->
+
<p>
                  <li> <a href="https://2015.igem.org/Team:BGU_Israel/Entrepreneurship">Entrepreneurship</a></li>
+
The <b>mammalian cells and bacteria</b> used in all experiments are classified as <b>biosafety level 1 organisms</b>; all are harmless and were used under
                   
+
well-established protocols and with proper guidance and safety equipment.
                </ul>
+
</p>
            </li>
+
<p>
 
+
Since <b>mammalian cells</b> are very sensitive, they will not survive in case of accidental release. In order to minimize the same risk in <b>bacteria</b>
        </ul>
+
, we used only 2 types of antibiotics in the entire work (chloramphenicol for the backbone plasmid and ampicillin for all the rest), so the bacteria remain
    </div>
+
vulnerable to other antibiotic types. If bacteria from our experiments will accidently get released, they most likely get outcompeted by the naturally
    <!-- End of menu -->
+
occurring and better adapted bacteria around. Moreover, we used bacteria in our experiments only as an amplification tool (DH5&#945;) for our plasmids,
 
+
which are competent cells. The promoters we used are human promoters, so it is not likely that translation will occur in other bacteria. But even if the
</div>
+
plasmids will get transformed to other bacteria and translated, the proteins encoded in our plasmids are probably harmless, because there are few
 
+
components needed to create the Boomerang system.
 
+
</p>
 
+
<p>
 
+
We used <b>AAV</b> (Serotype 2) as our vector to transduce the three plasmids into the cells. Replication-defective recombinant AAV vectors, as the one we used in our
</p><p><br />
+
experiments, are non-infectious and non-hazardous materials as defined by <a href="https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=standards&p_id=10099" target="blank">OSHA 1919.1200</a>. Even tough, Production of Adeno-associated virus does fall within <b>biosafety Level 2</b> criteria due to the use of HEK293 cells in the production process. Since routine quality control on preclinical vectors does not
 +
include testing for cellular contaminants or for replication competent AAV, we should handle AAV with caution as potentially infectious material.
 +
</p>
 +
<p>
 +
Despite this disadvantage, our goal was to try and use a potentially in vivo vector, which has very high transduction percentage. Since AAV mediated gene
 +
therapy has already been approved for marketing at 2012 by the European Commission (Glybera - for treatment of LPLD - lipoprotein lipase deficiency. More information available <a href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002145/human_med_001480.jsp&mid=WC0b01ac058001d124" target="_blank">here</a>), and it has some major advantages in comparison to other transduction methods (its ability to infect both nondividing and dividing cells, its ability to
 +
deliver the plasmids into the host cell's nuclear without integrating into the genome and the low pathogeny even in the WT replication-competent AAV)(<b>1</b>) we
 +
decided to use it with caution in Agilent kit (#240071 - AAV Helper-Free System). In this kit, the AAV ITR sequences and rep/cap genes are present on
 +
separate plasmids that lack homology and thus preventing production of recombinant wild-type virus.
 +
</p>
 +
<p>
 +
Yet, in order to minimize the work with viruses, it was decided that we will perform some of the experiments using calcium phosphate (CaP) as our
 +
transfection method instead of the viral vector.
 +
</p>
 +
<p>
 +
<h3>Safe Lab Work</h3>
 +
</p>
 +
<p><b>
 +
All lab work and experiments were done according to laboratory safety policies at Ben -Gurion University. The lab team was trained and escorted by lab
 +
members and instructors of Prof. Smadar Cohen lab for the entire time of our work to ensure the safety and health of team members and lab workers alike.
 +
</b></p>
 +
<p>
 +
Since not all team members had experience in genetic engineering lab before, all lab work was done under the supervision and guidance of at least one of
 +
the senior team members, who already had experience in that field.
 +
</p>
 +
<p>
 +
The <b><u>main</u></b> safety aspects of our daily routine in the lab included 3 parts:
 
</p>
 
</p>
<div id="wikicontent-container">
 
    <div id="wikicontent">
 
       
 
        <br /><br />
 
       
 
<h2>Safety in iGEM</h2>
 
 
<p>Please visit <a href="https://2015.igem.org/Safety">the main Safety page</a> to find this year's safety requirements & deadlines, and to learn about safe & responsible research in iGEM.</p>
 
 
<p>On this page of your wiki, you should write about how you are addressing any safety issues in your project. The wiki is a place where you can <strong>go beyond the questions on the safety forms</strong>, and write about whatever safety topics are most interesting in your project. (You do not need to copy your safety forms onto this wiki page.)</p>
 
 
 
<h4>Safe Project Design</h4>
 
 
<p>Does your project include any safety features? Have you made certain decisions about the design to reduce risks? Write about them here! For example:</p>
 
 
 
<ul>
 
<ul>
<li>Choosing a non-pathogenic chassis</li>
+
<li>
<li>Choosing parts that will not harm humans / animals / plants</li>
+
<u>Personal safety:</u>
<li>Substituting safer materials for dangerous materials in a proof-of-concept experiment</li>
+
all working in the lab was done with gloves, safety glasses, closed leather shoes and lab coats.
<li>Including an "induced lethality" or "kill-switch" device</li>
+
</li>
</ul>
+
<p>
 
+
Working with the virions was done inside biosafety cabinets. The virions were placed in designated tools, and we used filtered pipet tips to prevent sample
<h4>Safe Lab Work</h4>
+
carry-over contamination. After each work with virions (preparation or infection), UV light was turned on in the cabinets for two rounds (approx. 40 min).
 
+
</p>
<p>What safety procedures do you use every day in the lab? Did you perform any unusual experiments, or face any unusual safety issues? Write about them here!</p>
+
<li>
 
+
<u>Keeping our benches clean and organized:</u>
<h4>Safe Shipment</h4>
+
work benches were cleaned and sterilized with ethanol at the end of every work day. Waste was separated to viral waste, Biologic waste and regular
 
+
waste. The viral waste first went through two rounds of UV light inside the biosafety cabinets, and afterwards it was autoclaved, along with the
<p>Did you face any safety problems in sending your DNA parts to the Registry? How did you solve those problems?</p>
+
biologic waste.
 
+
</li>
 +
<li>
 +
<u>Special areas for different types of work - our lab was divided into 3 parts:</u>
 +
</li>
  
 +
<p>
 +
The first part of the lab was designated to the regular lab work (plasmid purification, restriction analysis and etc.).The second part (fume hood and a
 +
nearby bench) was designated to work with ethidium bromide and gel-electrophoresis only. The third part was for working with mammalian cells and virions
 +
(biosafety cabinets, separated culture room, bench in other laboratory).
 +
</p>
 +
<div>
 +
<img src="https://static.igem.org/mediawiki/2015/5/54/OurLab-updated.jpg" height="500px" width="800px">
 
</div>
 
</div>
 
+
</ul>
 
+
<p>
</div>
+
<h4>Safe Shipment</h4>
</div>
+
</div>
+
 
+
 
+
 
+
<div id="social-footer">
+
<a id="gotop" href="#"></a>
+
 
+
 
+
 
+
 
+
<div id="follow">
+
  <h2>Follow us:</h2>
+
  <div>
+
    <a id="adress" href="http://igembgu2015hp.wix.com/boomerang" target="blank"></a>
+
    <a id="mail" href="mailto:igembgu2015@gmail.com "></a>
+
    <a id="facebook" href="https://www.facebook.com/iGEMBGU" target="blank"></a>
+
    <a id="twitter" href="https://twitter.com/BGU_iGEM" target="blank"></a>
+
    <a id="youtube" href="http://player.vimeo.com/video/110058399" target="blank"></a>
+
  </div>
+
</div>
+
 
+
 
+
 
+
 
+
  <div id="Div2">
+
  <h2>Address:</h2>
+
  <p> <br />
+
  <p> <br />
+
 
+
</div>
+
 
+
</div>
+
 
+
 
+
 
</p>
 
</p>
 
+
<p>
 
+
We didn't face any special safety problems in sending our DNA parts.
<!-- Saved in parser cache with key 2013_igem_org:pcache:idhash:107-0!1!0!!en!2!edit=0 and timestamp 20150808061127 -->
+
<div class="printfooter"></div>
+
<div id="catlinks"><div id='Div1' class='catlinks catlinks-allhidden'></div></div> <!-- end content -->
+
<div class="visualClear"></div>
+
</div>
+
    </div>
+
<!-- PAGE FOOTER -- ITEMS FROM COLUMN ! HAVE BEEN MOVED HERE  -- RDR  -->
+
<div class="visualClear"></div>
+
    <div id='footer-box' class='noprint'>
+
        <div id="footer">
+
                  <div id="f-copyrightico"><a href="http://creativecommons.org/licenses/by/3.0/"><img src="http://i.creativecommons.org/l/by/3.0/88x31.png" alt="Attribution 3.0 Unported" width="88" height="31" /></a></div>    
+
            <ul id="f-list">
+
+
 
+
  <!-- Recentchanges is not handles well DEBUG -->
+
+
 
+
            </ul>
+
        </div> <!-- close footer -->
+
       
+
    </div> <!-- close footer-box -->
+
+
<script>    if (window.runOnloadHook) runOnloadHook();</script>
+
<!-- Served in 0.149 secs. --></body>
+
 
+
 
+
 
</p>
 
</p>
<!-- Saved in parser cache with key 2015_igem_org:pcache:idhash:1062-0!1!0!!en!2!edit=0 and timestamp 20150823083101 -->
+
<p>
<div class="printfooter">
+
<h4>References</h4>
Retrieved from "<a href="https://2015.igem.org/Team:BGU_Israel/Team">https://2015.igem.org/Team:BGU_Israel/Team</a>"</div>
+
(1) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Federico Mingozzi, Katherine A. High. Nature Reviews Genetics. 2011 May;12:341-355. doi: 10.1038/nrg2988.
<div class="visualClear"></div>
+
<br /><a href="http://www.ncbi.nlm.nih.gov/pubmed/21499295">http://www.ncbi.nlm.nih.gov/pubmed/21499295</a>
</div>
+
</p>
    </div>
+
<!-- finish HERE ----------------------------------------------------------------------------------------------->
<!-- PAGE FOOTER -- ITEMS FROM COLUMN ! HAVE BEEN MOVED HERE  -- RDR  -->
+
<div class="visualClear"></div>
+
+
<script>    if (window.runOnloadHook) runOnloadHook();</script>
+
</div>
+
</body>
+
  
 +
              </div>
 +
            </div>
 +
          </div>
 +
      </div>
 +
  <div class="visualClear"></div>
 +
  <br /><br /><br /><br /><br /><br /><br /><br />
 
</html>
 
</html>
 +
 +
{{BGU_Israel/footer}}

Latest revision as of 18:02, 18 September 2015

Team:BGU Israel



Safety

Safe Project Design

In Boomerang project, we used bacteria, mammalian cells and virions.

The mammalian cells and bacteria used in all experiments are classified as biosafety level 1 organisms; all are harmless and were used under well-established protocols and with proper guidance and safety equipment.

Since mammalian cells are very sensitive, they will not survive in case of accidental release. In order to minimize the same risk in bacteria , we used only 2 types of antibiotics in the entire work (chloramphenicol for the backbone plasmid and ampicillin for all the rest), so the bacteria remain vulnerable to other antibiotic types. If bacteria from our experiments will accidently get released, they most likely get outcompeted by the naturally occurring and better adapted bacteria around. Moreover, we used bacteria in our experiments only as an amplification tool (DH5α) for our plasmids, which are competent cells. The promoters we used are human promoters, so it is not likely that translation will occur in other bacteria. But even if the plasmids will get transformed to other bacteria and translated, the proteins encoded in our plasmids are probably harmless, because there are few components needed to create the Boomerang system.

We used AAV (Serotype 2) as our vector to transduce the three plasmids into the cells. Replication-defective recombinant AAV vectors, as the one we used in our experiments, are non-infectious and non-hazardous materials as defined by OSHA 1919.1200. Even tough, Production of Adeno-associated virus does fall within biosafety Level 2 criteria due to the use of HEK293 cells in the production process. Since routine quality control on preclinical vectors does not include testing for cellular contaminants or for replication competent AAV, we should handle AAV with caution as potentially infectious material.

Despite this disadvantage, our goal was to try and use a potentially in vivo vector, which has very high transduction percentage. Since AAV mediated gene therapy has already been approved for marketing at 2012 by the European Commission (Glybera - for treatment of LPLD - lipoprotein lipase deficiency. More information available here), and it has some major advantages in comparison to other transduction methods (its ability to infect both nondividing and dividing cells, its ability to deliver the plasmids into the host cell's nuclear without integrating into the genome and the low pathogeny even in the WT replication-competent AAV)(1) we decided to use it with caution in Agilent kit (#240071 - AAV Helper-Free System). In this kit, the AAV ITR sequences and rep/cap genes are present on separate plasmids that lack homology and thus preventing production of recombinant wild-type virus.

Yet, in order to minimize the work with viruses, it was decided that we will perform some of the experiments using calcium phosphate (CaP) as our transfection method instead of the viral vector.

Safe Lab Work

All lab work and experiments were done according to laboratory safety policies at Ben -Gurion University. The lab team was trained and escorted by lab members and instructors of Prof. Smadar Cohen lab for the entire time of our work to ensure the safety and health of team members and lab workers alike.

Since not all team members had experience in genetic engineering lab before, all lab work was done under the supervision and guidance of at least one of the senior team members, who already had experience in that field.

The main safety aspects of our daily routine in the lab included 3 parts:

  • Personal safety: all working in the lab was done with gloves, safety glasses, closed leather shoes and lab coats.
  • Working with the virions was done inside biosafety cabinets. The virions were placed in designated tools, and we used filtered pipet tips to prevent sample carry-over contamination. After each work with virions (preparation or infection), UV light was turned on in the cabinets for two rounds (approx. 40 min).

  • Keeping our benches clean and organized: work benches were cleaned and sterilized with ethanol at the end of every work day. Waste was separated to viral waste, Biologic waste and regular waste. The viral waste first went through two rounds of UV light inside the biosafety cabinets, and afterwards it was autoclaved, along with the biologic waste.
  • Special areas for different types of work - our lab was divided into 3 parts:
  • The first part of the lab was designated to the regular lab work (plasmid purification, restriction analysis and etc.).The second part (fume hood and a nearby bench) was designated to work with ethidium bromide and gel-electrophoresis only. The third part was for working with mammalian cells and virions (biosafety cabinets, separated culture room, bench in other laboratory).

Safe Shipment

We didn't face any special safety problems in sending our DNA parts.

References

(1) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Federico Mingozzi, Katherine A. High. Nature Reviews Genetics. 2011 May;12:341-355. doi: 10.1038/nrg2988.
http://www.ncbi.nlm.nih.gov/pubmed/21499295